ARCALIS leads the world as the most advanced CDMO for mRNA vaccines and therapeutics.

ARCALIS is a contract development and manufacturing organization ("CDMO") for messenger RNA (mRNA) vaccines and therapeutics. The company was jointly established by Axcelead, Inc., the first drug discovery platform company in Japan, and Arcturus Therapeutics, a US-based, global, late-stage clinical mRNA medicines company. mRNA is a new therapeutic and vaccine modality that was only recently commercialized in the wake of the Coronavirus infection, but the challenge toward practical application has been ongoing since the 1990s. Research and development of mRNA have begun targeting not only infectious diseases, but also therapeutics and vaccines for various applications, such as rare diseases, cancer, regenerative medicine, and genome editing.The company provides drug discovery support, CMC development, and manufacturing support services for mRNA therapeutics and vaccines to pharmaceutical and biotech companies. These services are backed by expertise accumulated in Arcturus in the fields of manufacturing technologies.

The following movie provides a brief explanation of ARCALIS


Company name ARCALIS, Inc.
Founded February 12, 2021
Minamisoma(Head Office) 320-20 Kawauchisako, Shimoota aza, Haramachi, Minamisoma, Fukushima 975-0041Google Map
Kashiwanoha 226-39 Wakashiba, Kashiwa, Chiba 277-0871Google Map
Representative Director,
President and CEO
Satoshi Takamatsu
Financial month December
Capital 100 million yen
Group Companies Arcturus Therapeutics, Inc. , Axcelead, Inc.

To know more about ARCALIS


Please select the content of your inquiry.